Cann Group (ASX:CAN) Market Cap: A$6.64 Mil (As of Jun. 25, 2026)


What is Cann Group Market Cap?

Cann Group ASX:CAN -25.00% Market Cap is A$6.64 Mil as of Jun. 25, 2026. The stock has 7 warning signs investors should review. Among 1,023 Drug Manufacturers companies, Cann Group ranks worse than 90.62% on this metric.

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Cann Group's share price for the quarter that ended in Dec. 2025 was A$0.009. Cann Group's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 1,570.81 Mil. Therefore, Cann Group's market cap for the quarter that ended in Dec. 2025 was A$14.14 Mil.

Cann Group's quarterly market cap declined from Dec. 2024 (A$20.91 Mil) to Jun. 2025 (A$6.36 Mil) but then increased from Jun. 2025 (A$6.36 Mil) to Dec. 2025 (A$14.14 Mil).

Cann Group's annual market cap declined from Jun. 2023 (A$46.63 Mil) to Jun. 2024 (A$12.48 Mil) and declined from Jun. 2024 (A$12.48 Mil) to Jun. 2025 (A$6.36 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Cann Group's Enterprise Value for Today is A$20.65 Mil.


Cann Group  (ASX:CAN) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Cann Group Market Cap Related Terms


Cann Group Market Cap Historical Data

* Premium members only.

The historical data trend for Cann Group's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cann Group Market Cap Chart

Cann Group Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Market Cap
Get a 7-Day Free Trial Premium Member Only 94.49 96.62 46.63 12.48 6.36

Cann Group Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.03 12.48 20.91 6.36 14.14

ASX:CAN vs ZTS: Market Cap Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cann Group's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cann Group Market Cap vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cann Group's Market Cap distribution charts can be found below:

* The bar in red indicates where Cann Group's Market Cap falls into.



Cann Group Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Cann Group's Market Cap for the fiscal year that ended in Jun. 2025 is calculated as

Market Cap (A: Jun. 2025 )=Share Price (A: Jun. 2025 )*Shares Outstanding (EOP) (A: Jun. 2025 )
=A$0.01*636.176
=A$6.36

Cann Group's Market Cap for the quarter that ended in Dec. 2025 is calculated as

Market Cap (Q: Dec. 2025 )=Share Price (Q: Dec. 2025 )*Shares Outstanding (EOP) (Q: Dec. 2025 )
=A$0.009*1570.813
=A$14.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Market Cap →
What does a Market Cap of A$6.64 Mil mean?
Cann Group (ASX:CAN) has a Market Cap of A$6.64 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Cann Group and its competitors. According to the industry distribution chart, Cann Group ranks #927 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 90.6%.
Is Cann Group's Market Cap too high?
Cann Group's current Market Cap is A$6.64 Mil. Based on the distribution chart, Cann Group ranks #927 out of 1023 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Cann Group's Market Cap compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cann Group ranks #927 out of 1023 companies for Market Cap. This places Cann Group in the lower half of its industry. The industry median Market Cap is 206.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 206.50, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Cann Group and its competitors. For the Drug Manufacturers industry, the median Market Cap is 206.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cann Group's current Market Cap is A$6.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cann Group stock overvalued right now?
Based on GuruFocus' analysis, Cann Group (ASX:CAN) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.00 — trading 85% below its estimated fair value. The current Market Cap is A$6.64 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Cann Group (ASX:CAN), the current Market Cap is A$6.64 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cann Group Business Description

Other Exchanges CNGGF:USA
Address 262-276 Lorimer Street, Ground Floor, Port Melbourne, VIC, AUS, 3207
Cann Group Ltd is engaged in the cultivation of medicinal cannabis for both medicinal and research purposes under the licenses and permits issued to the company, the development and manufacture (via third-party arrangements) of finished product formulations. Geographically, the company operates in Europe and Australia. The company derives maximum revenue from Australia.